Deans' stroke musings: Study examines role of intraventricular transplantation of bone marrow mesenchymal stem cell in stroke patients

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, May 11, 2016

Study examines role of intraventricular transplantation of bone marrow mesenchymal stem cell in stroke patients

It may be safely transplanted but is that because they all died and joined the cerebrospinal fluid in the brain? Or did they survive and not do anything because they didn't connect to anything? Without even knowing the answers to these two simple questions this research has to be considered a complete failure.
http://www.news-medical.net/news/20160503/Study-examines-role-of-intraventricular-transplantation-of-bone-marrow-mesenchymal-stem-cell-in-stroke-patients.aspx

Winner of the American Association of Neurological Surgeons (AANS) International Travel Scholarship, Asra Al Fauzi, MD, IFAANS, presented his research, Intraventricular Transplantation of Autologous Bone Marrow Mesenchymal Stem Cell in Hemorrhagic Stroke, during the 2016 AANS Annual Scientific Meeting.
This research investigates the role of intraventricular transplantation using bone marrow mesenchymal stem cell in stroke patients.
This study was one group (eight patients) pre- and post-test design. Subjects were selected from supratentorial hemorrhagic stroke patients after six months of treatment with stable neurological deficits with NIHSS of 5-25. Clinical outcomes were measured using the NIHSS scale six months after transplantation. Bone marrow was aspirated, taken from the same patient under aseptic conditions, and expansion of MSC took three to four weeks. All patients were administered a mean of 20 × 106 cells intraventricularly.
The result showed improvement of the NIHSS score in five patients after treatment, and the rest were in the same condition. No important adverse events derived from transplant or surgery was observed during a six-month follow up.
The study demonstrates that bone marrow mesenchymal stem cell can be transplanted intraventricularly with excellent tolerance and without complications. Stem cell transplantation aiming to restore function in stroke is both safe and feasible. Further randomized controlled trials are needed to evaluate efficacy.

Source:

American Association of Neurological Surgeons (AANS)